Document:

Exhibit 10.1

 

WAIVER AGREEMENT

 

This Waiver Agreement
(this “Agreement”) is entered into as of the 10th day of July, 2018, by and between Helios and Matheson Analytics
Inc., a Delaware corporation with offices located at Empire State Building, 350 5th Avenue, New York, New York 10118 (the “Company”)
and the investor signatory hereto (the “Holder”), with reference to the following facts:

 

A. Prior to the date
hereof, in connection with an offering (the “November Financing”) pursuant to that Securities Purchase Agreement
dated as of November 6, 2017 (as amended, the “November Securities Purchase Agreement”), by and among the Company,
the Holder and the other buyers signatory thereto (collectively, the “November Buyers”), the Company issued
to the November Buyers, among other things, senior convertible notes and senior secured convertible notes (collectively, the “November
Notes”), in each case, convertible into shares of the Company’s common stock, $0.01 par value per share (the “Common
Stock”), in accordance with the terms thereof.

 

B. Prior to the date
hereof, in connection with an offering (the “January Financing”) pursuant to that Securities Purchase Agreement
dated as of January 11, 2017 (the “January Securities Purchase Agreement”) by and between the Company and the
Holder (the “January Buyer”), the Company issued to such January Buyer, a senior convertible note and a senior
secured convertible note (collectively, the “January Notes”), in each case, convertible into shares of Common
Stock in accordance with the terms thereof.

 

C. Prior to the date
hereof, in connection with an offering (the “June Financing”) pursuant to that Securities Purchase Agreement
dated as of June 21, 2018 (the “June Securities Purchase Agreement”, and together with the November Securities
Purchase Agreement and the January Securities Purchase Agreement, the “Existing Securities Purchase Agreements”)
by and among the Company, the Holder and the other buyers signatory thereto (collectively, the “June Buyers”
and together with the November Buyers and the January Buyer, the “Existing Buyers”), the Company issued to the
June Buyers senior convertible notes (collectively, the “June Notes”, and together with the November Notes and
the January Notes, the “Existing Notes”), convertible into shares of Common Stock in accordance with the terms
thereof. Capitalized terms not defined herein shall have the meaning as set forth in the June Securities Purchase Agreement.

 

D. The Company currently
desires to consummate a Subsequent Placement on or prior to July 16, 2018, pursuant to which the Company shall issue up to 80 million
shares of Common Stock (collectively, the “New Shares”) and/or warrants (the “New Warrants”)
to purchase common stock (collectively, the “New Warrant Shares”, and together with the New Shares and the New
Warrants, the “New Securities”) (the “New Proposed Offering”).

 

E. The Company desires
to obtain (i) a waiver from the Holder (x) of any obligation by the Company to effect any redemption of any of the Existing Notes
as a result of the consummation of the New Proposed Offering, and (y) to reduce the aggregate number of shares reserved for issuance
for the November Notes by the number of shares of Common Stock per each November Buyer as set forth on Schedule I attached
hereto, and (ii) a deferral from the Holder until the fourth (4th) Trading Day after the time of pricing of the New
Proposed Offering any right that the holders of the Existing Notes may have to adjust the Conversion Price (as defined in the applicable
Existing Note) of any such Existing Notes solely as a result of the issuance of the New Securities in the New Proposed Offering
(collectively, the “Waivers”).

 

     

     

    

 

NOW, THEREFORE, in consideration
of the foregoing premises and the mutual covenants hereinafter contained, the Company and the Holder agree as follows:

 

1. Waivers.
As of the time the Company and the Holder, in its capacity as the “Required Holders” (as defined in each of the Existing
Securities Purchase Agreement) pursuant to each of the Existing Securities Purchase Agreements, each have duly executed and delivered
this Agreement (the “Effective Time”), the following shall apply (the “Consents and Waivers”):

 

(a) The Holder
hereby consents to the New Proposed Offering (i) defers any right that the holders of Existing Notes may have to adjust the Conversion
Price (as defined in the applicable Existing Notes) pursuant to Section 7 of such Existing Note solely as a result of the issuance
of the New Securities in the New Proposed Offering until the fourth (4th) Trading Day after the time of pricing of the
New Proposed Offering and (ii) waives any prohibition that may exist under any provision of the Transaction Documents (as defined
in each Existing Securities Purchase Agreement) with respect to the issuance of the New Securities.

 

(b) The Holder
hereby waives any obligation of the Company, to consummate (i) any Subsequent Placement Optional Redemption (as defined in the
November Notes) with respect to any November Notes of any November Buyer, (ii) any Subsequent Placement Optional Redemption (as
defined in the January Notes) with respect to any January Notes of any January Buyer and, (iii) any Optional Redemption (as defined
in the June Notes) with respect to any June Notes of any June Buyer, in each case, solely to the extent such right arises from
the consummation of the New Proposed Offering. For the avoidance of doubt, nothing herein shall be deemed to waive the right of
a Holder to have any Optional Redemption arising primarily as a result of events other than the consummation of the New Proposed
Offering to be satisfied with proceeds from the New Proposed Offering.

 

(c) Solely
with respect to the period commencing on the date hereof and ending on the Stock Split Stockholder Approval Deadline, the Holder
hereby waives any obligation of the Company to reserve more than an aggregate of 124,000,000 shares of Common Stock for conversion
of the November Notes and the January Notes.

 

Notwithstanding the foregoing,
if the consummation of the New Proposed Offering does not occur on or prior to July 16, 2018, the foregoing Consents and Waivers
shall automatically terminate, de novo, and shall be null and void.

 

5. Limitation
of Consents and Waiver. The Consents and Waivers set forth in this Agreement constitute a one-time consent and waiver and
are limited to the matters expressly waived herein and should not be construed as an indication that the Holder would be willing
to agree to any future modifications to, consent of, or waiver of any of the terms of any other agreement, instrument or security
or any modifications to, consents of, or waiver of any default that may exist or occur thereunder.

 

    	 	2	 

     

    

 

6. Ratifications.
Except as otherwise expressly provided herein, each of the Transaction Documents (as defined in each Existing Securities Purchase
Agreement) is, and shall continue to be, in full force and effect and is hereby ratified and confirmed in all respects.

 

7. Disclosure
of Transaction. The Company shall, on or before 8:30 a.m., New York City Time, on or prior to the first business day after
the date of this Agreement, file a Current Report on Form 8-K describing the terms of the transactions contemplated hereby in the
form required by the 1934 Act and attaching the form of this Agreement as an exhibit to such filing (including all attachments,
the “8-K Filing”). From and after the filing of the 8-K Filing, the Company shall have disclosed all material,
non-public information (if any) provided up to such time to the Holder by the Company or any of its Subsidiaries or any of their
respective officers, directors, employees or agents. In addition, effective upon the filing of the 8-K Filing, the Company acknowledges
and agrees that any and all confidentiality or similar obligations under any agreement with respect to the transactions contemplated
by the Exchange Documents or as otherwise disclosed in the 8-K Filing, whether written or oral, between the Company, any of its
Subsidiaries or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and any of the Holder
or any of their affiliates, on the other hand, shall terminate. Neither the Company, its Subsidiaries nor the Holder shall issue
any press releases or any other public statements with respect to the transactions contemplated hereby; provided,
however, the Company shall be entitled, without the prior approval of the Holder, to make a press release or other
public disclosure with respect to such transactions (i) in substantial conformity with the 8-K Filing and contemporaneously therewith
or (ii) as is required by applicable law and regulations (provided that in the case of clause (i) the Holder shall be consulted
by the Company in connection with any such press release or other public disclosure prior to its release). Without the prior written
consent of the Holder (which may be granted or withheld in the Holder’s sole discretion), except as required by applicable
law, the Company shall not (and shall cause each of its Subsidiaries and affiliates to not) disclose the name of the Holder in
any filing, announcement, release or otherwise.

 

8. Fees.
The Company shall reimburse Kelley Drye & Warren LLP, counsel to the Holder, for its fees and expenses in connection with the
structuring, documentation, negotiation of this Waiver, and all other outstanding amounts owed by the Company to Kelley Drye &
Warren LLP pursuant to any other agreement by and between the Company and the Holder, in an aggregate amount equal to $15,000.

 

9. Independent
Nature of Holder's Obligations and Rights. The obligations of the Holder under this Agreement are several and not joint
with the obligations of any other Existing Buyer (each, an “Other Holder”), and the Holder shall not be responsible
in any way for the performance of the obligations of any Other Holder under any other agreement (each, an “Other Agreement”).
Nothing contained herein or in any Other Agreement, and no action taken by the Holder pursuant hereto, shall be deemed to constitute
the Holder and Other Holders as a partnership, an association, a joint venture or any other kind of entity, or create a presumption
that the Holder and Other Holders are in any way acting in concert or as a group with respect to such obligations or the transactions
contemplated by this Agreement or any Other Agreement and the Company acknowledges that, to the best of its knowledge, the Holder
and the Other Holders are not acting in concert or as a group with respect to such obligations or the transactions contemplated
by this Agreement or any Other Agreement. The Company and the Holder confirm that the Holder has independently participated in
the negotiation of the transactions contemplated hereby with the advice of its own counsel and advisors. The Holder shall be entitled
to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement, and it
shall not be necessary for any Other Holder to be joined as an additional party in any proceeding for such purpose.

 

10. Miscellaneous
Provisions. Section 9 of the June Securities Purchase Agreement is hereby incorporated by reference herein, mutatis mutandis.

 

[The remainder of the
page is intentionally left blank]

 

    	 	3	 

     

    

 

IN WITNESS WHEREOF,
the Holder and the Company have executed this Agreement as of the date set forth on the first page of this Agreement.

 

	 	COMPANY:
	 	 	 
	 	HELIOS AND MATHESON ANALYTICS INC.
	 	 	 	 
	 	By:	/s/
    Theodore Farnsworth
	 	 	Name:	Theodore Farnsworth
	 	 	Title:	Chief Executive Officer

 

     

     

    

 

IN WITNESS WHEREOF,
Holder and the Company have executed this Agreement as of the date set forth on the first page of this Agreement.

 

	 	HOLDER:
	 	 
	 	HUDSON BAY MASTER FUND LTD
	 	 	 
	 	By:	/s/ Yoav Roth
	 	 	Name: Yoav Roth
	 		Title: Authorized Signatory

 

     

     

    

 

SCHEDULE I

 

	Name of Holders	 	Reduction of Shares to be Reserved for November Notes	 
	 	 	 	 
	Hudson Bay Master Fund Ltd.	 	 	40,000,000	 
	Other Holders of November Notes (on a pro rata basis)	 	 	40,000,000	 
	TOTAL	 	 	80,000,000EX-10.1

 Exhibit 10.1 

ASSIGNMENT AGREEMENT 

This Assignment Agreement (this “Agreement”), dated as of February 1, 2018 (the “Effective Date”), is
between NantOmics, LLC (“NantOmics), a Delaware limited liability company, and NantHealth, Inc., a Delaware corporation (“NantHealth”). NantOmics and NantHealth are each sometimes referred to herein as a
“Party” and collectively as “Parties.” 
 RECITALS 

WHEREAS, NantCell, Inc. (NantCell) acquired Liquid Genomics, Inc., a Delaware corporation (“Liquid Genomics”), pursuant to an
Agreement and Plan of Merger (“Merger Agreement”), dated as of March 31, 2017, among NantCell, Liquid Genomics, Bio Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and the stockholder representative,
under which Merger Sub was merged with and into Liquid Genomics. 
 WHEREAS, following the transactions consummated pursuant to the Merger
Agreement, NantOmics acquired 100 shares of common stock, par value $0.001 per share, of Liquid Genomics (the “LG Shares”), along with all of NantCell’s rights and obligations under the Merger Agreement, resulting in Liquid
Genomics becoming a wholly-owned subsidiary of NantOmics (the “NO/LG Acquisition”). 
 WHEREAS, as consideration for the
NO/LG Acquisition, NantOmics paid to NantCell $7,240,536.43, representing the amount paid by NantCell for its acquisition of Liquid Genomics and funding of Liquid Genomics following such acquisition without any markup. 

WHEREAS, NantOmics desires to assign, and NantHealth desires to assume, the LG Shares and all rights and obligations under the Merger
Agreement in exchange for consideration equal to the amount paid by NantOmics for the NO/LG Acquisition, plus an amount equal to the funding of Liquid Genomics without any markup since the NO/LG acquisition, all on the terms and conditions set forth
herein. 
 NOW, THEREFORE, in consideration of the mutual representations, warranties, covenants and agreements contained herein, and other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 
 1.
Assignment of LG Shares. NantOmics agrees to convey, assign, transfer and deliver to NantHealth on the Closing Date (defined below) all of NantOmics’s right, title and interest in, to and under the LG Shares. Following the foregoing
conveyance, assignment and transfer, Liquid Genomics will be a wholly-owned subsidiary of NantHealth. 
 2. Assignment of Merger
Agreement. NantOmics agrees to convey, assign, transfer and deliver to NantHealth on the Closing Date all of NantOmics’ rights and obligations under the Merger Agreement and all ancillary agreements and documents referred to therein. 

3. Consideration. In consideration of the transactions contemplated by this Agreement, NantHealth agrees to convey, assign, transfer and
deliver to NantOmics: 
 3.1 on the Closing Date, Series A-2 equity units of NantOmics owned by
NantHealth (“NO Units”) in an amount equal to (i) $7,240,536.43 plus (ii) the amount of funding provided by NantOmics to Liquid Genomics, without markup, for its operations between the NO/LG Acquisition and December 31,
2017 (the “Initial NO Units”); and 

 3.2 by May 31, 2018, NO Units in an amount equal to the funding provided by NantOmics to
Liquid Genomics, without markup, for its operations between January 1, 2018 and the Closing Date. 
 The parties agree that the per-unit book value of NO Units on NantHealth’s balance sheet as of December 31, 2017 shall be used for purposes of determining the number of NO Units to be conveyed to NantOmics under Sections 3.1 and
3.2. 
 4. Closing. 
 4.1
The closing of the transaction contemplated under this Agreement (“Closing”) shall be consummated at 1:00 PM, California time, on February 28, 2018 or such other date and time as may be agreed upon by the Parties. The Closing
shall be deemed to have become effective as of 11:59 PM., California time, on the date on which the Closing is actually held, and such time and date are referred to herein as the “Closing Date.” 

4.2 At the Closing: 
 (a)
NantOmics will deliver to NantHealth: (i) certificates representing the LG Shares, duly endorsed (or accompanied by duly executed powers); (ii) an assignment of the Merger Agreement; and (iii) such other bills of sale, assignments and
other instruments of transfer or conveyance as NantHealth may reasonably request or as may be otherwise necessary to evidence and effect the sale, assignment, transfer, conveyance and delivery of the LG Shares and Merger Agreement. 

(b) NantHealth will deliver to NantOmics: (i) the Initial NO Units (defined above), duly endorsed (or accompanied by duly executed
powers) and (ii) such other bills of sale, assignments and other instruments of transfer or conveyance as NantOmics may reasonably request or as may be otherwise necessary to evidence and effect the sale, assignment, transfer, conveyance and
delivery of the NO Units. 
 4.3 Between the Effective Date and Closing, NantOmics shall cause Liquid Genomics to operate and carry on its
business only in the ordinary course and in all material respects as presently operated. 

  
 - 2 - 

 5. NantOmics Representations and Warranties. NantOmics represents and warrants to
NantHealth, as of the Effective Date and Closing Date, that: (a) it is duly organized and existing in good standing as a limited liability company under the laws of the State of Delaware and that it has full power and authority to execute and
deliver, and to perform all of its obligations under, this Agreement; (b) the execution, delivery and performance of this Agreement has been authorized by all necessary limited liability company action, and does not and will not:
(i) violate or conflict with any law, rule, regulation, order, writ, judgment, injunction, decree, determination, award, contract, agreement or understanding presently in effect applicable to NantOmics or (ii) require any authorization,
consent, approval, license, exemption by or from, or filing or registration with, any court, executive or legislative body, governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign; (c) this Agreement
constitutes a legal, valid and binding obligation of NantOmics enforceable against NantOmics in accordance with its terms; and (d) NantOmics has good title to and is the sole owner of all of the LG Shares, free and clear of all liens, charges
and any encumbrances of any kind whatsoever (and NantHealth will receive good title to the LG Shares, free and clear of all liens, charges and any encumbrances of any kind whatsoever). 

6. NantHealth Representations and Warranties. NantHealth represents and warrants to NantOmics that, as of the Effective Date and Closing
Date: (a) it is duly organized and existing in good standing as a corporation under the laws of the State of Delaware and that it has full power and authority to execute and deliver, and to perform all of its obligations under, this Agreement;
(b) the execution, delivery and performance of this Agreement has been authorized by all necessary corporate action, and does not and will not: (i) violate or conflict with any law, rule, regulation, order, writ, judgment, injunction,
decree, determination, award, contract, agreement or understanding presently in effect applicable to NantHealth or (ii) require any authorization, consent, approval, license, exemption by or from, or filing or registration with, any court,
executive or legislative body, governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign; (c) this Agreement constitutes a legal, valid and binding obligation of NantHealth enforceable against NantHealth
in accordance with its terms; and (d) NantHealth has good title to and is the sole owner of all of the NO Units, free and clear of all liens, charges and any encumbrances of any kind whatsoever (and NantOmics will receive good title to the NO
Units, free and clear of all liens, charges and any encumbrances of any kind whatsoever). 
 7. Further Assurances. At any time or
from time to time after the date hereof, the Parties agree to cooperate with each other, and at the request of the other Party, to execute and deliver any further instruments or documents and to take all such further action as the other Party may
reasonably request in order to evidence or effectuate the consummation of the transactions contemplated hereby and to otherwise carry out the intent of the Parties hereunder. 

8. Successors and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective
successors and assigns of the Parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the Parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities
under or by reason of this Agreement, except as expressly provided in this Agreement. 
 9. Governing Law. This Agreement shall be
governed and construed in accordance with the laws of the State of Delaware, without giving effect to any choice or conflict of laws, provisions or rules that would cause the application of laws of any jurisdiction other than the State of Delaware.

 10. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly
delivered and be valid and effective for all purposes. 

  
 - 3 - 

 11. Enforcement. Each Party hereto acknowledges that money damages may not be an adequate
remedy in the event of a breach of this Agreement or that any of the covenants or agreements in this Agreement are not performed by the Parties in accordance with its terms, and it is therefore agreed that in addition to and without limiting any
other remedy or right each Party may have, each Party may have the right to an injunction, temporary restraining order or other equitable relief in any court of competent jurisdiction enjoining any such breach and enforcing specifically the terms
and provisions hereof. 
 12. Integration; Entire Agreement. This Agreement and the documents referred to herein or delivered pursuant
hereto contain the entire understanding of the Parties with respect to the subject matter hereof and thereof. There are no agreements, representations, warranties, covenants or undertakings with respect to the subject matter hereof and thereof other
than those expressly set forth herein and therein. Except as otherwise expressly set forth herein, this Agreement embodies the complete agreement and understanding among the Parties hereto with respect to the subject matter hereof and supersedes and
preempts any prior understandings, agreements or representations by or among the Parties, written or oral, that may have related to the subject matter hereof in any way. 

  
 - 4 - 

 IN WITNESS WHEREOF, the parties have executed this Assignment Agreement as of the date first
written above. 
  

			
	NANTOMICS, LLC	  	NANTHEALTH, INC.
		
	By: /s/ Charles
Kim                                        
	  	By: /s/ Paul
Holt                                         
   
	Name: Charles Kim	  	Name: Paul Holt
	Title: Executive Vice President	  	Title: Chief Financial Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]